Ibrutinib treatment improves T cell number and function in CLL patients.

  title={Ibrutinib treatment improves T cell number and function in CLL patients.},
  author={Meixiao Long and Kyle A. Beckwith and Priscilla Do and Bethany L Mundy and Amber L Gordon and Amy M. Lehman and Kami Maddocks and Carolyn M. Cheney and Jeffrey A. Jones and Joseph M. Flynn and Leslie A. Andritsos and Farrukh T Awan and Joseph A Fraietta and Carl H June and Marcela V Maus and Jennifer A Woyach and Michael A. Caligiuri and Amy J. Johnson and Natarajan Muthusamy and John C. Byrd},
  journal={The Journal of clinical investigation},
  volume={127 8},
BACKGROUND Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected… CONTINUE READING
Highly Cited
This paper has 178 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS
5 Citations
62 References
Similar Papers


Publications citing this paper.


Publications referenced by this paper.
Showing 1-10 of 62 references

Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response

  • Y Sun
  • Sci Signal
  • 2015
Highly Influential
18 Excerpts

https://doi.org/10.1172/JCI89756 The Journal of Clinical Investigation

  • V. ter
  • Schus Downloaded from http://www.jci.org on…
  • 2017
2 Excerpts

Similar Papers

Loading similar papers…